Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths

Sarepta Therapeutics shares plunged over 35% after the company refused an FDA request to halt shipments of its gene therapy, Elevidys, following a third patient death linked to liver injury, a known side effect. This highly unusual defiance of regulatory guidance, which typically sees companies comply with such requests, places the future of its flagship Duchenne's muscular dystrophy treatment in significant doubt and adds to the company's recent challenges, including major layoffs. The FDA has indicated it may take further action, signaling heightened regulatory scrutiny on gene therapies with emerging safety signals.

Analysis

Sarepta Therapeutics has entered into a high-stakes confrontation with the FDA by refusing a direct request to halt shipments of its flagship gene therapy, Elevidys. This highly unusual defiance follows the death of a third patient linked to its treatments, exacerbating an already severe safety crisis that has seen its stock plummet over 35% to $14.07. The three deaths were attributed to liver injury, a known side effect, with two involving older boys treated with Elevidys and a third involving a patient in a separate trial for an experimental therapy, which the FDA has now placed on hold. The company's credibility with investors is further damaged by its failure to disclose the third death during a recent conference call, a move that drew sharp criticism from Wall Street analysts. While Sarepta maintains its own review found "no new or changed safety signals" for the younger patient cohort it continues to serve, its confrontational stance places the future of Elevidys in significant jeopardy. The FDA's public statement that it is "not afraid to take immediate action" signals a strong likelihood of impending formal regulatory measures, which could override the company's decision and result in a protracted and value-destructive battle.

Key Decisions for Investors

• Investors should recognize the extreme regulatory risk stemming from Sarepta's direct conflict with the FDA, which could lead to a forced market withdrawal of its key revenue driver, Elevidys.
• The lack of management transparency regarding the third patient death represents a significant governance red flag, warranting a reassessment of leadership credibility and the potential for further negative disclosures.
• Closely monitor for any formal enforcement action from the FDA, as a mandatory recall would be a primary downward catalyst and invalidate the company's current commercial strategy.
• Given the confluence of severe safety signals, heightened regulatory hostility, and collapsing market confidence, it may be prudent to reduce exposure or exercise extreme caution until the drug's market status is definitively resolved.